Panacea Pharmaceuticals, Inc.
Records under this name other than the patents Panacea Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Panacea Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,576,069 | Treatment for chemotherapy-induced cognitive impairment Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,702,591 | Therapeutic Cancer Vaccine Targeted to Haah (Aspartyl-[asparaginyl]-Beta-Hydroxylase Formerly held In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 9,744,223 | Therapeutic Cancer Vaccine Targeted to Haah (ASPARTYL-[ASPARAGINYL]-BETA-HYDROXYLASE) Formerly held In force (reinstated) · Low confidence | In force (reinstated) | Low confidence | |
| US 7,605,133 | Isolated Peptides to Treat Alpha-Synuclein Diseases Lapsed on the fee record Ended Oct 20, 2021 · High confidence | Lapsed on the fee record | Ended Oct 20, 2021 | High confidence |
| US 7,521,479 | Methods of Treating Prion Disease in Mammals Formerly held Term ended Term ended Apr 16, 2021 · High confidence | Term ended | Term ended Apr 16, 2021 | High confidence |
| US 8,153,414 | Microbial delivery system Formerly held Term ended Term ended Dec 6, 2020 · From the USPTO record | Term ended | Term ended Dec 6, 2020 | From the USPTO record |
| US 7,456,179 | Methods of treating ischemic related conditions Lapsed on the fee record Ended Nov 25, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 25, 2020 | From the USPTO record |
| US 6,835,370 | Diagnosis and Treatment of Malignant Neoplasms Formerly held Term ended Term ended Nov 8, 2019 · Medium confidence | Term ended | Term ended Nov 8, 2019 | Medium confidence |
| US 6,238,925 | Method for determining likelihood of developing clinical tolerance Formerly held Term ended Term ended Jan 28, 2019 · From the USPTO record | Term ended | Term ended Jan 28, 2019 | From the USPTO record |
| US 6,780,971 | Compositions for Inhibiting the Aggregation Pathway of Alpha-Synuclein Lapsed on the fee record Ended Aug 24, 2012 · High confidence | Lapsed on the fee record | Ended Aug 24, 2012 | High confidence |